RAD1901 MedChemExpress (MCE)

Product Name	Elacestrant
Synonyms	RAD-1901;Elacestrant;2-Naphthalenol, 6-[2-[ethyl[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydro-, (6R)-
CAS	722533-56-4
EINECS
Chemical Formula	C30H38N2O2
Molecular Weight	458.63492
inchi
Package	10 mM * 1 mL;10 mM * 1 mL;1 mg;1 mg;5 mg;5 mg;10 mg;10 mg
Price	Email to quote
Descriptions	Elacestrant Elacestrant MedChemExpress (MCE) HY-19822 722533-56-4 RAD1901 99.80% 4°C, sealed storage, away from moisture and light In solvent : -80°C, 6 months Descriptions Elacestrant Elacestrant MedChemExpress (MCE) HY-19822 722533-56-4 RAD1901 99.80% 4°C, sealed storage, away from moisture and light In solvent : -80°C, 6 months -20°C, 1 month (sealed storage, away from moisture and light) Room temperature in continental US may vary elsewhere. Elacestrant (RAD1901) is an orally available and selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also can inhibit growth of ER+ breast cancer cell lines in vitro and in vivo. Elacestrant (RAD1901 0.5 nM-10 µM 48 h) exhibits dose-dependent inhibition of ERα expression, with a EC50 of 0.6 nM in MCF-7 cells[1]. Elacestrant (0-1 µM 48 h) inhibits proliferation of Estradiol (E2)-stimulated MCF-7 cells in a dose-dependent manner, with an EC50 of 4 pM[1]. Elacestrant (0-1 µM 24 or 48 h) results in a dose-dependent and marked decrease in estrogen receptor protein expression in MCF7, T47D, and HCC1428 cells[2]. Elacestrant (0.01, 0.1, 1.0 µM) decreases expression of progesterone receptor (PGR, PR an ER target gene), in both MCF7 and T47D cell lines[2]. Elacestrant (0.3-120 mg/kg p.o. single daily for 40 days) antagonizes E2-mediated uterine stimulation in a dose-dependent manner in vivo[1]. Elacestrant (30, 60 mg/kg p.o. single daily for 4 weeks) induces complete tumor growth inhibition in mice[2]. Tumor growth inhibition is maintained for 4 weeks after Elacestrant withdrawal[2]. IC50: 48 nM (ERα), 870 nM (ERβ)[1] Cellular Effect Cell Line Type Value Description References \| \| \| \| \| \| \| \| \| \| [1]. Garner F, et al. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015 Oct 26(9):948-56. [Content Brief] [2]. Bihani T, et al. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models. Clin Cancer Res. 2017 Aug 15 23(16):4793-4804. [Content Brief]
Supplier Website	https://www.medchemexpress.com/Elacestrant.html
Last Update	2025-05-21 16:50:25

MedChemExpress (MCE) also provides

Thalidomide-4-O-C2-NH2

Category: Signaling Pathways
CAS: 2341840-99-9
Last Update: 2025-05-21 16:50:25

PPARα-MO-1

Category: Signaling Pathways
CAS: 810677-36-2
Last Update: 2025-05-21 16:50:25

Netupitant N-oxide

Category: Signaling Pathways
CAS: 910808-11-6
Last Update: 2025-05-21 16:50:25

MK-0812

Category: Signaling Pathways
CAS: 624733-88-6
Last Update: 2025-05-21 16:50:25

TS-011

Category: Signaling Pathways
CAS: 339071-18-0
Last Update: 2025-05-21 16:50:25

SCH 530348 sulfate

Category: Signaling Pathways
CAS: 705260-08-8
Last Update: 2025-05-21 16:50:25

BAG 956

Category: Signaling Pathways
CAS: 853910-02-8
Last Update: 2025-05-21 16:50:25

YM758

Category: Signaling Pathways
CAS: 312752-85-5
Last Update: 2025-05-21 16:50:25


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	https://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact